Advertisement

World Journal of Surgery

, Volume 34, Issue 9, pp 2155–2161 | Cite as

Comparing Hepatic Resection and Transarterial Chemoembolization for Barcelona Clinic Liver Cancer (BCLC) Stage B Hepatocellular Carcinoma: Change for Treatment of Choice?

  • Chin-Ta Lin
  • Kuo-Feng Hsu
  • Teng-Wei Chen
  • Jyh-Cherng Yu
  • De-Chuan Chan
  • Chih-Yung Yu
  • Tsai-Yuan Hsieh
  • Hsiu-Lung Fan
  • Shih-Ming Kuo
  • Kuo-Piao Chung
  • Chung-Bao Hsieh
Article

Abstract

Background

Compared to transarterial chemoembolization (TACE) for patients with hepatocellular carcinoma (HCC), stage B in the Barcelona Clinic Liver Cancer (BCLC) classification, the role of hepatic resection remains unclear. The present study compared the long-term outcome of hepatic resection with TACE in the treatment of BCLC stage B HCC.

Methods

A total of 171 patients with BCLC stage B, Child’s classification A (Child A), HCC were included in this retrospective study. Of these, 93 patients underwent hepatic resection (group I) and 73 patients received TACE (group II). We evaluated the long-term outcome and therapy-related mortality in both groups. The risk factors of mortality were assessed. The survival curve was analyzed by the Kaplan–Meier method.

Results

The 1-, 2-, and 3-year overall survival rates for the two groups after hepatic resection and TACE were 83%, 62%, 49% and 39%, 5%, 2%, respectively (P < 0.0001). We did not observe significant differences in the therapy-related mortality between the two groups (P = 0.78). Treatment modality and serum albumin level were independent risk factors for survival by Cox regression analysis.

Conclusions

Our study demonstrated that hepatic resection for BCLC stage B, Child A HCC patients had better survival rates than TACE group. Thus, hepatic resection is indicated in selected patients with BCLC stage B.

Keywords

Tace Hepatic Resection Serum Albumin Level Barcelona Clinic Liver Cancer Transarterial Chemoembolization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750CrossRefPubMedGoogle Scholar
  3. 3.
    Wakabayashi H, Ushiyama T, Ishimura K et al (2003) Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol 82:98–103CrossRefPubMedGoogle Scholar
  4. 4.
    Lai EC, Fan ST, Lo CM et al (1995) Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 221:291–298CrossRefPubMedGoogle Scholar
  5. 5.
    Mor E, Kaspa RT, Sheiner P et al (1998) Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 129:643–653PubMedGoogle Scholar
  6. 6.
    Ota K, Teraoka S, Kawai T (1995) Donor difficulties in Japan and Asian countries. Transplant Proc 27:83–86PubMedGoogle Scholar
  7. 7.
    Mazziotti A, Grazi GL, Cavallari A (1998) Surgical treatment of hepatocellular carcinoma on cirrhosis: a Western experience. Hepatogastroenterology 45(Suppl 3):1281–1287PubMedGoogle Scholar
  8. 8.
    Fan ST, Lo CM, Liu CL et al (1999) Hepatic resection for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229:322–330CrossRefPubMedGoogle Scholar
  9. 9.
    Okuda K, Ohtsuki T, Obata H et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928CrossRefPubMedGoogle Scholar
  10. 10.
    Greene FL, Page DL, Fleming ID (2002) Liver including intrahepatic bile ducts. In: American Joint Committee on Cancer Staging Manual. Springer, New York Google Scholar
  11. 11.
    Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524CrossRefPubMedGoogle Scholar
  12. 12.
    Marrero JA, Fontana RJ, Barrat A et al (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707–716CrossRefPubMedGoogle Scholar
  13. 13.
    Levy I, Sherman M (2002) Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50:881–885CrossRefPubMedGoogle Scholar
  14. 14.
    El-Serag HB, Marrero JA, Rudolph L et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763CrossRefPubMedGoogle Scholar
  15. 15.
    Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130CrossRefPubMedGoogle Scholar
  16. 16.
    Ringe B, Pichlmayr R, Wittekind C et al (1991) Surgical treatment of hepatocellular carcinoma: experience with hepatic resection and transplantation in 198 patients. World J Surg 15:270–285CrossRefPubMedGoogle Scholar
  17. 17.
    Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127(Suppl 1):S179–S188CrossRefPubMedGoogle Scholar
  18. 18.
    Capussotti L, Borgonovo G, Bouzari H et al (1994) Results of major hepatic resection for large primary liver cancer in patients with cirrhosis. Br J Surg 81:427–431CrossRefPubMedGoogle Scholar
  19. 19.
    Shuto T, Hirohashi K, Kubo S et al (1999) Efficacy of major hepatic resection for large hepatocellular carcinoma. Hepatogastroenterology 46:413–416PubMedGoogle Scholar
  20. 20.
    Hanazaki K, Kajikawa S, Shimozawa N et al (2001) Hepatic resection for large hepatocellular carcinoma. Am J Surg 181:347–353CrossRefPubMedGoogle Scholar
  21. 21.
    Lee NH, Chau GY, Lui WY et al (1998) Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter. Br J Surg 85:1654–1657CrossRefPubMedGoogle Scholar
  22. 22.
    Hanazaki K, Kajikawa S, Shimozawa N et al (2002) Hepatic resection for hepatocellular carcinoma in diameter of > or =10 cm. Hepatogastroenterology 49:518–523PubMedGoogle Scholar
  23. 23.
    Poon RT, Fan ST, Wong J (2002) Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 194:592–602CrossRefPubMedGoogle Scholar
  24. 24.
    Ng KK, Vauthey JN, Pawlik TM et al (2005) Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 12:364–373CrossRefPubMedGoogle Scholar
  25. 25.
    Hsieh CB, Yu CY, Tzao C et al (2006) Prediction of the risk of hepatic failure in patients with portal vein invasion hepatoma after hepatic resection. Eur J Surg Oncol 32:72–76CrossRefPubMedGoogle Scholar
  26. 26.
    European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50:227–242CrossRefPubMedGoogle Scholar
  27. 27.
    Makuuchi M, Hasegawa H, Yamazaki S (1985) Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 161:346–350PubMedGoogle Scholar
  28. 28.
    Pringle JH (1908) Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg 48:541–549CrossRefPubMedGoogle Scholar
  29. 29.
    Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739CrossRefPubMedGoogle Scholar
  30. 30.
    O Suilleabhain CB, Poon RT, Yong JL et al (2003) Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90:325–331CrossRefGoogle Scholar
  31. 31.
    Yoshioka H, Sato M, Sonomura T et al (1997) Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma. Semin Oncol 24:S6PubMedGoogle Scholar
  32. 32.
    Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564–568CrossRefPubMedGoogle Scholar
  33. 33.
    Bruix J, Llovet JM, Castells A et al (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578–1583CrossRefPubMedGoogle Scholar
  34. 34.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442CrossRefPubMedGoogle Scholar
  35. 35.
    Ishizawa T, Hasegawa K, Aoki T et al (2008) Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134:1908–1916CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2010

Authors and Affiliations

  • Chin-Ta Lin
    • 1
  • Kuo-Feng Hsu
    • 1
  • Teng-Wei Chen
    • 1
  • Jyh-Cherng Yu
    • 1
  • De-Chuan Chan
    • 1
  • Chih-Yung Yu
    • 2
  • Tsai-Yuan Hsieh
    • 3
  • Hsiu-Lung Fan
    • 1
  • Shih-Ming Kuo
    • 1
  • Kuo-Piao Chung
    • 4
  • Chung-Bao Hsieh
    • 1
  1. 1.Division of General Surgery, Department of SurgeryTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan
  2. 2.Department of RadiologyTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan
  3. 3.Division of Gastroenterology, Department of MedicineTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan
  4. 4.Graduate Institute of Health Care Organization AdministrationNational Taiwan UniversityTaipeiTaiwan

Personalised recommendations